Use of truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease

Journal of Clinical Oncology

Volumn 15, Issue 6, 1997, Pages 2322-2328

  Chan, Daniel W ^a   Beveridge, Roy A ^a   Muss, Hyman ^a   Fritsche, Herbert A ^a   Hortobagyi, Gabriel ^a   Theriault, Richard ^a   Kiang, David ^a   Kennedy, B J ^a   Evelegh, Mike ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; DISEASE ASSOCIATION; EARLY DIAGNOSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; PREDICTION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RECEPTOR BINDING; RELIABILITY;

EID: 0030965064     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.6.2322     Document Type: Article

References (30)

1. Jensen JL, Maclean GD, Suresh MR, et al: Possible utility of serum determinations of CA 125 and CA 27.29 in breast cancer management. Int J Biol Markers 6:1-6, 1991
2. Price MR: High molecular weight epithelial mucins as markers in breast cancer. Eur J Cancer Clin Oncol 24:1799-1804, 1988
3. Stahli C, Caravatti M, Aeschbacher M, et al: Mucin-like carcinoma-associated antigen defined by three monoclonal antibodies against different epitopes. Cancer Res 48:6799-6802, 1988
4. Beveridge RA, Chan DW, Bruzek D, et al: A new biomarker in monitoring breast cancer: CA 549. J Clin Oncol 6:1815-1821, 1988
5. Hayes DF, Zurawski VR, Kufe DW: Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 4:1542-1550, 1986
6. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, et al: Molecular cloning and expression and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 265:15286-15293, 1990
7. Peterson JA, Ceriani RL: Breast mucin and associated antigens in diagnosis and therapy, in Ceriani RL (ed): Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis. New York, NY, Plenum, 1994, pp 2-3
8. Lesuffleur T, Zweibaum A, Real FX: Mucins in normal and neoplastic human gastrointestinal tissues. Crit Rev Oncol Hematol 17:153-180, 1994
9. Kiang DT, Greenberg LJ, Kennedy BJ: Tumor marker kinetics in the monitoring of breast cancer. Cancer 65:193-199, 1990
10. O'Hanlon DM, Kenn MJ, Kent PJ, et al: A prospective evaluation of CA15-3 in stage I carcinoma of the breast. J Am Coll Surg 180:210-212, 1995
11. Safi F, Kohler I, Rottinger E, et al: The value of tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen. Cancer 68:574-582, 1991
12. Silver HK, Archibald BL, Ragaz J: Relative operating characteristic analysis and group modeling for tumor markers: Comparison of CA 15.3, carcinoembryonic antigen, and mucin-like carcinoma-associated antigen in breast carcinoma. Cancer Res 51:1904-1909, 1991
13. Hayes DF: Tumor markers for breast cancer. Clinical utilities and future prospects. Hematol Oncol Clin North Am 8:485-506, 1994
14. Ballesta AM, Molina R, Filella X, et al: Carinoembryonic antigen in staging and follow-up of patients with solid tumors. Tumor Biol 16:32-41, 1995
15. Reddish MA, Helbrecht N, Almeida AF, et al: Epitope mapping of Mab B27.29 within the peptide core of the malignant breast carcinoma-associated mucin antigen coded for by the human MUC 1 gene. J Tumor Marker Oncol 7:19-27, 1992
16. Fleiss J: Statistical Methods for Rates and Proportions. New York, NY, Wiley, 1981
17. Donegan WL, Spratt JS: Cancer of the Breast. Philadelphia, PA, Saunders, 1988
18. Kufe D, Inghirami G, Abe M, et al: Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 3:223-232, 1984
19. Hilkens J, Buijs F, Hilgers J, et al: Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer 34:197-206, 1984
20. Devine PL, Duroux MA, Quin RJ, et al: CA 15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer. Breast Cancer Res Treat 34:245-251, 1995
21. Estabrook A, Chen J, Oster M, et al: Clinical value of BCA-225: A new breast cancer serum marker. J Tumor Marker Oncol 9:111-118, 1994
22. Gion M, Mione R, Nascimbe O, et al: The tumor associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases. Br J Cancer 63:809-813, 1991
23. O'Hanlon DM, Kerin MJ, Kent P, et al: An evaluation of preoperative CA 15-3 measurement in primary breast carcinoma. Br J Cancer 71:1288-1291, 1995
24. Molina R, Zanon G, Filella X, et al: Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 36:41-48, 1995
25. Gourevitch MM, Mensdorf-Pouilly S, Litvinov SV, et al: Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. Br J Cancer 72:934-938, 1995
26. DeVita VT Jr: The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant therapy of cancer. Cancer 51:1209-1220, 1983
27. GIVIO Investigators: Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. JAMA 271:1587-1592, 1994
28. Jager W: The early detection of disseminated (metastasized) breast cancer by serial tumour marker measurements. Eur J Cancer Prev 2:133-139, 1993
29. McQuellan RP, Muss HB, Hoffman SL, et al: Patient preferences for treatment of metastatic breast cancer: A study of women with early-stage breast cancer. J Clin Oncol 13:858-868, 1995
30. Muss HB, Tell GS, Case LD, et al: Perceptions of follow-up care in women with breast cancer. Am J Clin Oncol 14:55-59, 1991